Late Stage RAS Oncology Pipeline Will Face Heavy Costs Yet Eventually Support Stable Long Term Outlook

Catalysts

About Revolution Medicines

Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations, with a pipeline of RAS(ON) inhibitors across pancreatic, lung and colorectal indications.

What are the underlying business or industry changes driving this perspective?

• Although late stage RAS(ON) programs such as daraxonrasib and zoldonrasib are advancing across multiple Phase III trials in pancreatic and lung cancer, the company still relies on successful readouts and potential approvals in complex tumor settings. This could affect the timing and scale of future revenue.
• Although there is a growing focus in oncology on biomarker driven, targeted therapies for RAS mutant tumors, the need for combination regimens with chemotherapy, PD 1 agents or PRMT5 inhibitors may keep treatment costs and development complexity high. This could weigh on net margins once commercialized.
• Although the company has access to substantial liquidity with US$2.03b in cash and investments and up to US$1.75b of remaining committed capital from Royalty Pharma, GAAP operating expenses guided to US$1.6b to US$1.7b for 2026 signal heavy ongoing spend. This may delay any move toward positive earnings.
• Although the pipeline covers major RAS driven cancers such as pancreatic, non small cell lung and colorectal cancer, the heterogeneous biology in colorectal cancer and the need for multi drug combinations make it harder to define clear registrational paths. This could limit the breadth and timing of revenue contribution from that indication.
• Although the company is building a global commercial infrastructure, including U.S. field sales and regional capabilities in Europe and Japan, the upfront commercial build before any approved product keeps G&A expenses elevated and extends the period of reported net losses.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Revolution Medicines compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• Revolution Medicines currently has no revenue. The bearish analysts are forecasting revenue to reach $838.8 million by June 2029.
• The bearish analysts are not forecasting that Revolution Medicines will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Revolution Medicines's profit margin will increase from 0.0% to the average US Biotechs industry of 18.9% in 3 years.
• If Revolution Medicines's profit margin were to converge on the industry average, you could expect earnings to reach $158.7 million (and earnings per share of $0.61) by about June 2029, up from -$1.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.5 billion in earnings, and the most bearish expecting $-1.7 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 305.2x on those 2029 earnings, up from -27.6x today. This future PE is greater than the current PE for the US Biotechs industry at 16.6x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.18%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Multiple late stage programs are moving through 8 registrational trials with breakthrough therapy designations and plans to begin commercialization. If any of these programs receive regulatory approvals in large RAS driven indications such as pancreatic and non small cell lung cancer, the associated sales ramp could lift the share price and materially change revenue and earnings compared with a flat share price view.
• The company is heavily funding a broad clinical and commercial build out, with 2026 GAAP operating expenses guided to US$1.6b to US$1.7b and significant stock based compensation and noncash items. If this spending successfully converts into approved products, the shift from large net losses to potential positive earnings could support a higher valuation instead of a stable share price.
• Revolution Medicines has access to US$2.03b in cash and investments plus up to US$1.75b of remaining committed capital from Royalty Pharma. Effective use of this funding to expand trials, combinations and global commercialization could support a larger business footprint than implied by a flat share price, with knock on effects for future revenue and earnings power.
• Breakthrough therapy designations, a commissioners national priority voucher and multiple collaborations with companies such as Tango Therapeutics, Bristol Myers Squibb, Amgen and Summit Therapeutics align the pipeline with long term trends toward biomarker guided, combination based oncology. If these efforts lead to broad adoption in RAS addicted cancers, the resulting treatment share and pricing could lift net margins and earnings above what a stable share price would imply.
• The company is investing to become a global commercial stage oncology enterprise, including building U.S. field sales teams and regional capabilities in Europe and Japan. If this infrastructure leads to successful launches across several RAS(ON) assets rather than a single product story, the diversification of revenue streams and potential operating leverage could put upward pressure on the share price relative to expectations of it remaining flat.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Revolution Medicines is $151.0, which represents up to two standard deviations below the consensus price target of $188.57. This valuation is based on what can be assumed as the expectations of Revolution Medicines's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $263.0, and the most bearish reporting a price target of just $151.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $838.8 million, earnings will come to $158.7 million, and it would be trading on a PE ratio of 305.2x, assuming you use a discount rate of 7.2%.
• Given the current share price of $178.17, the analyst price target of $151.0 is 18.0% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.